Cyclerion Therapeutics (CYCN) Operating Income (2018 - 2025)

Cyclerion Therapeutics' Operating Income history runs 8 years deep, the most recent figure standing at -$1.0 million for Q3 2025.

• In Q3 2025, Operating Income rose 10.82% year-over-year to -$1.0 million; the TTM figure through Sep 2025 stood at -$3.6 million (up 38.68% YoY), while the FY2024 annual figure was -$3.6 million, up 71.99% from the prior year.
• Operating Income was -$1.0 million for Q3 2025 at Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $502000.0 in Q4 2024 to a low of -$16.2 million in Q2 2021.
• Historically, Operating Income has averaged -$5.9 million across 5 years, with a median of -$3.3 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Operating Income tumbled 33.13% in 2023, then soared 127.97% in 2024.
• A 5-year view of Operating Income shows it stood at -$14.3 million in 2021, then jumped by 68.93% to -$4.5 million in 2022, then jumped by 59.71% to -$1.8 million in 2023, then jumped by 127.97% to $502000.0 in 2024, then slumped by 300.4% to -$1.0 million in 2025.
• The last three Operating Income figures came in at -$1.0 million (Q3 2025), -$1.7 million (Q2 2025), and -$1.5 million (Q1 2025), per Business Quant data.